Chi-Med’s surufatinib bags US fast track designations by Selina McKee | Apr 17, 2020 | News | 0 The drug has a unique dual mechanism of action that could help fulfil an unmet medical need Read More
NICE backs Afinitor, Sutent for neuroendocrine tumours by Selina McKee | Jun 28, 2017 | News | 0 Novartis’ Afinitor and Pfizer’s Sutent have received backing from the National Institute for Health and Care Excellence as cost-effective treatment options for certain neuroendocrine tumours (NETs). Read More